Biotech Beckons in Bonny Scotland

Jack, Lorna
October 2005
Bio-IT World;Oct2005, Vol. 4 Issue 10, p46
Academic Journal
Focuses on the network of global partnerships and collaborations that contributed to the success of the life science sector in Scotland. Opportunities available for collaboration with Scottish biomedical innovators that motivate U.S. biotechnology firms to invest in the industry; Role of venture capital firms Scottish Equity Partners and the Scottish Development International economic agency in attracting inward investment and promote international development; Agreement entered into by Scottish biopharmaceutical company Cyclacel with U.S.-based Genzyme.


Related Articles

  • THE HEART OF IRELAND'S ECONOMIC DEVELOPMENT STRATEGY. Martin, Micheál // BioPharm International;Dec2005 Supplement, p8 

    The article discusses the biotech sector of Ireland. In recent years, Ireland has attracted major biotech players including Genzyme Corp. and Centocor, Inc. In the early 2005, venture capital activity in Ireland increased by 25.7% in comparison with the same period last year, and 70% of the...

  • Swedish Biotech: A Golden Opportunity. Bergstrand, Björn // Bio-IT World;Oct2005, Vol. 4 Issue 10, p42 

    Assesses the performance of the biotechnology industry in Sweden and the business opportunities it offers to industrial and financial investors. List of venture capital companies that focus solely on life sciences and biotechnology; Implication of the high-profile partnerships between U.S. and...

  • Investors stay keen. Gardner, Darran // Electronics Weekly;Jan2004 Supplement, p4 

    The global technology sector may have found it tougher to raise funds last year, but some Scottish companies bucked the trend as their technology became too exciting for investors to resist. Scottish Equity Partners (SEP) was an early investor in Edinburgh-based Wolfson Microelectronics, which...

  • Untitled.  // Electronics Weekly;5/12/2004, Issue 2146, p16 

    Scottish Equity Partners picked up a venture capital accolade last week in recognition of its work on last year's IPO for Wolfson Microelectronics. It was the largest technology flotation in Great Britain for three years.

  • Medtronic and Genzyme form joint venture targeting cardiac repair.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p14 

    Reports on the joint ventures between Medtronic Inc. and Genzyme Corp. for the development of new treatments of cardiovascular disease.

  • Genzyme acquires Ilex Oncology in $1bn deal.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p18 

    Reports on the acquisition of Ilex Oncology Inc. by Genzyme Corp. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • Random/Order gains strategic partners. Goldrich, Robert // SHOOT;08/27/99, Vol. 40 Issue 34, p1 

    Reports that Random/Order Information and Entertainment has sparked interest on the venture capital arena with its plan to build a roster of strategic partners. Teamup with agencies in developing advertising-based content and programming; Companies that have confirmed their interest in becoming...

  • What to do when your technology is good but a licence is terminated. Cox, Manon; Adams, Dan // Journal of Commercial Biotechnology;Oct2005, Vol. 12 Issue 1, p22 

    One of the biggest challenges in the biotech industry is to secure sufficient funding to support product or technology development. Partnering with companies that have cash and expertise – which, for the most part are larger biotech or pharmaceutical industries – may for many small...

  • Biotech is Still Booming. Clapp, Donna // BioPharm International;May2009, Vol. 22 Issue 5, pB1 

    The article discusses the growth of biotechnology industry. According to the author, biotechnology is one of various industries that continue to grow quickly. It cites that biotech companies have posted an increased record amounts of venture capital, and that value of mergers, acquisitions, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics